全球和我国HBV感染免疫耐受期患者人数估计更正说明

庄辉

doi:10.3969/j.issn.1001-5256.2021.04.012

全球和我国HBV感染免疫耐受期患者人数估计更正说明

DOI: 10.3969/j.issn.1001-5256.2021.04.012

庄辉^,

北京大学基础医学院病原生物学系和感染病中心，北京 100191

详细信息

通信作者:
庄辉，zhuangbmu@126.com

中图分类号: R512.62
计量
- 文章访问数: 494
- HTML全文浏览量: 84
- PDF下载量: 109
- 被引次数: 0
出版历程
- 收稿日期: 2021-03-24
- 录用日期: 2021-03-24
- 出版日期: 2021-04-20

Correction note on the estimated number of patients in the immune-tolerant phase of hepatitis B virus infection in China and globally

Hui ZHUANG^,

Department of Microbiology and Center of Infectious Diseases, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China

摘要

- 乙型肝炎病毒 /
- 免疫耐受 /
- 出版更正
- Hepatitis B virus /
- Immune Toleranc /
- Published Erratum

HTML全文

图 1 全球HBV免疫耐受期患者人数估计

下载: 全尺寸图片幻灯片

图 2 我国HBV免疫耐受期患者人数估计

下载: 全尺寸图片幻灯片

参考文献(13)

[1]	ZHUANG H. Should patients in the immune tolerance stage of chronic hepatitis B virus infection be treated?[J]. J Clin Hepatol, 2021, 37(2): 272-277. DOI: 10.3969/j.issn.1001-5256.2021.02.007. 庄辉. 慢性HBV感染免疫耐受期应否治疗?[J]. 临床肝胆病杂志, 2021, 37(2): 272-277. DOI: 10.3969/j.issn.1001-5256.2021.02.007.
[2]	Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study[J]. Lancet Gastroenterol Hepatol, 2018, 3(6): 383-403. DOI: 10.1016/S2468-1253(18)30056-6.
[3]	RUFAI T, MUTOCHELUH M, KWARTENG K, et al. The prevalence of hepatitis B virus E antigen among Ghanaian blood donors[J]. Pan Afr Med J, 2014, 17: 53. DOI: 10.11604/pamj.2014.17.53.3390.
[4]	GILL HH, MAJUMDAR PD, DHUNJIBHOY KR, et al. Prevalence of hepatitis B e antigen in pregnant women and patients with liver disease[J]. J Assoc Physicians India, 1995, 43(4): 247-248. http://europepmc.org/abstract/MED/8713262
[5]	SAGNELLI E, STROFFOLINI T, MELE A, et al. Chronic hepatitis B in Italy: New features of an old disease-approaching the universal prevalence of hepatitis B e antigen-negative cases and the eradication of hepatitis D infection[J]. Clin Infect Dis, 2008, 46(1): 110-113. DOI: 10.1086/524074.
[6]	RABBI FJ, REZWAN MK, SHIRIN T. HBeAg/anti-HBe, alanine aminotransferase and HBV DNA levels in HBsAg positive chronic carriers[J]. Bangladesh Med Res Counc Bull, 2008, 34(2): 39-43. DOI: 10.3329/bmrcb.v34i2.1173.
[7]	NAKAGOMI O, SUZUKI T, OYAMADA H, et al. Serological survey of hepatitis B virus (HBV) markers in out- and in-patients in a university hospital[J]. Tohoku J Exp Med, 1984, 142(2): 227-228. DOI: 10.1620/tjem.142.227.
[8]	MCMAHON BJ, HOLCK P, BULKOW L, et al. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus[J]. Ann Intern Med, 2001, 135(9): 759-768. DOI: 10.7326/0003-4819-135-9-200111060-00006.
[9]	WU CH, HSU TY, KUNG FT, et al. Changes in the prevalence of HBsAg and HBeAg: A study of 8696 parturients in a well vaccinated area[J]. Sci Rep, 2017, 7(1): 1212. DOI: 10.1038/s41598-017-01234-0.
[10]	STASI C, SILVESTRI C, BERNI R, et al. Clinical epidemiology of chronic viral hepatitis B: A Tuscany real-word large-scale cohort study[J]. World J Hepatol, 2018, 10(5): 409-416. DOI: 10.4254/wjh.v10.i5.409.
[11]	BRANCACCIO G, NARDI A, MADONIA S, et al. The present profile of chronic hepatitis B virus infection highlights future challenges: An analysis of the Multicenter Italian MASTER-B cohort[J]. Dig Liver Dis, 2019, 51(3): 438-442. DOI: 10.1016/j.dld.2018.09.008.
[12]	GIANNINI EG, MARENCO S, BONI S, et al. Therapeutic management of chronic hepatitis B in clinical practice: A region-wide survey[J]. J Clin Gastroenterol, 2015, 49(3): 228-234. DOI: 10.1097/MCG.0000000000000106.
[13]	Bureau of Disease Prevention and Control, Ministry of Health, Chinese Center for Disease Control and Prevention. Seroepidemiological survey of hepatitis B in Chinese population[M]. Beijing: People's Medical Publishing House, 2011: 29. 卫生部疾病预防控制局, 中国疾病预防控制中心. 全国人群乙型病毒性肝炎血清流行病学调查报告[M]. 北京: 人民卫生出版社, 2011: 29.